Management and Prevention of Nausea and Vomiting Supportive Care

Arrhythmia Risk Leads to Label Change for Zofran (07-9-2012)

Interim data from a recent clinical trial has indicated that a 32 mg single dose of Zofran® (ondansetron) may affect the electrical activity of the heart and could predispose patients to develop an abnormal heart rhythm. The U.S. Food and Drug Administration... Continue Reading

Study Suggests Long-acting Patch that Prevents Nausea and Vomiting Can Be Given in Combination with Intravenous Medication (02-9-2010)

Use of a combination of Sancuso® (granisetron transdermal system; a patch that delivers granisetron through the skin for up to five days) and intravenous granisetron appears to be safe and feasible. This approach may provide immediate and extended... Continue Reading